Edition:
United States

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Global Select Market

2.70USD
4:00pm EDT
Change (% chg)

$-0.05 (-1.82%)
Prev Close
$2.75
Open
$2.75
Day's High
$2.75
Day's Low
$2.65
Volume
6,570
Avg. Vol
4,063
52-wk High
$4.45
52-wk Low
$2.12

Select another date:

Mon, Aug 14 2017

BRIEF-Atyr Pharma qtrly ‍net loss per share $0.51​

* Atyr Pharma announces second quarter 2017 operating results and provides an update on innovative immunology pipeline

BRIEF-ATyr pharma enters into first amendment to loan and security agreement

* ATyr Pharma says on june 30, entered into first amendment to loan and security agreement with silicon valley bank and solar capital ltd - SEC filing

BRIEF-aTyr Pharma announces qtrly net loss per share, basic and diluted $0.56

* aTyr Pharma Inc - Qtrly net loss per share, basic and diluted $0.56

BRIEF-Atyr Pharma announces promising top-line results from Resolaris

* Atyr Pharma announces promising top-line results from Resolaris phase 1B/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy

BRIEF-aTyr Pharma appoints of Timothy P. Coughlin to its board

* aTyr Pharma announces appointment of TIMOTHY P. COUGHLIN to its board of directors Source text for Eikon: Further company coverage:

BRIEF-aTyr Pharma qtrly net loss per share attributable to common stockholders $0.53

* Atyr pharma -continues to expect that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into q3 of 2018

BRIEF-Atyr Pharma reports issuance of U.S. patent that extends patent protection of physiocrines

* Atyr Pharma announces issuance of U.S. patent that extends patent protection of physiocrines derived from 20 out of 20 human TRNA synthetases Source text for Eikon: Further company coverage:

BRIEF-Atyr Pharma receives EMA orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris

* Atyr Pharma receives ema orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris™ Source text for Eikon: Further company coverage:

BRIEF-Atyr Pharma receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris

* Atyr Pharma Receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris™ Source text for Eikon: Further company coverage:

Select another date: